Introduction
Sudden cardiac death (SCD) remains a major public health problem in the western world, with over 200 000 deaths reported annually in the USA alone [1] . The underlying mechanism is ventricular tachyarrhythmia in the overwhelming majority. However, the underlying substrate varies: ischemic heart disease in 75-80% cases; idiopathic cardiomyopathy in 10-15%; and 1-2% due to rare monogenic mutations in cardiac ion channels or associated proteins [2] . Even though the latter constitute only a small portion of SCDs, their study is imperative in understanding the mechanisms of SCD. In fact, the concept of evaluating the molecular mechanism of a monogenic arrhythmia syndrome to provide clues in probing the mechanism and improve therapy of more commonly acquired arrhythmogenic diseases has been proposed [3 ] . For example, mutations in the RyR2 Ca 2þrelease channel cause catecholaminergic polymorphic ventricular tachycardia (CPVT); acquired RyR2 dysfunction has been implicated in ventricular tachyarrhythmia and SCD in heart failure and may contribute to the pathogenesis of other diseases such as idiopathic cardio-myopathy or atrial fibrillation, with increased 'SR Ca 2þleak' being the common underlying mechanism. Furthermore, common variants in SCD genes may increase arrhythmia risk associated with 'environmental' factors (e.g., drugs, electrolytes, ischemia) [4 ,5] .
Newer study methods in genetics promise to enhance our understanding of disease mechanisms. For example, genome-wide association studies (GWASs), a highthroughput genotyping of a large number of single nucleotide polymorphisms (SNPs) correlating them to a phenotype, are clearly a step forward in investigating biologic pathways of disease causation [6 ] . Using this technique, SNP 'rs2824292' at locus 21q21 has been strongly associated with ventricular fibrillation after acute myocardial infarction, a major cause of SCD of which very little is known [7 ] . Interestingly, the gene closest to this SNP is CXADR, which encodes a viral receptor previously implicated in myocarditis and dilated cardiomyopathy (DCM) and has been identified as a modulator of cardiac conduction, but not implicated in arrhythmia susceptibility [7 ] . However, more studies need to be done to uncover a causal relationship, if one exists. The remainder of the review focuses on new candidate genes and new developments in diagnosis and treatment of SCD syndromes, subdivided into two major categories (Table 1) : syndromes associated with structurally normal hearts [CPVT, Brugada syndrome (BrS), long and short QT syndrome, and idiopathic ventricular fibrillation (IVF)] and syndromes associated with cardiomyopathic lesions [arrhythmogenic right ventricular cardiomyopathy (ARVC), DCM, hypertrophic cardiomyopathy (HCM), and left ventricular noncompaction].
Catecholaminergic polymorphic ventricular tachycardia
The number of mutations in RyR2(155) and CASQ2(15) linked to CPVT continues to grow since they were first described almost a decade ago (http://www.fsm.it/ cardmoc/ for updated list) [8] [9] [10] . Although the RyR2 binding proteins triadin and junctin have been suggested from murine models as additional candidates [11, 12] , human mutations have not yet been found. Among patients with exertional syncope, polymorphic ventricular tachycardia and normal QTc, nearly 50% have putative RyR2 mutations causing CPVT [13 ] and nearly 20% of these RyR2 mutations are de novo [13 ] . Because sporadic cases of CPVT can be due to germ-line mosaicism in one of the parents [13 ,14] , systematic genetic screening of the proband's siblings should be done even if standard methods fail to clearly detect the mutation in the parents [14] . A tiered approach in screening for RyR2 mutations due to clustering of known CPVT mutations in certain exons can be used to lower the cost [13 ] . It can be expected that newer technologies like the 'next-generation' gene sequencing will not only make it faster and cheaper to screen the entire RyR2 but will also abolish the need for sequencing these 'hot regions' for mutations.
Mechanistically, CPVT is a triggered arrhythmia that occurs due to delayed after-depolarization (DAD) due to spontaneous sarcoplasmic reticulum Ca 2þ release during catecholamine surge [ [26 ,27] , this suggests that multiple molecular mechanisms culminating in loss of function of SCNA5 may be the final common mechanism for BrS [29] . Mutations in the gene encoding glycerol-3-phosphate dehydrogenase 1-like enzyme by virtue of Na þ current reduction have been linked to BrS [30] . Furthermore, 'loss of function' mutations in cardiac Ca 2þ channel complex [31, 32] and mutation in KCNE3 leading to increase in the amplitude of I to current [33] have also been implicated in BrS. However, the genetic cause of BrS remains elusive in the remaining 70-80% of patients [26 ] .
The class I a antiarrhythmic agent and I to current blocker quinidine seems quite effective in suppressing ventricular tachyarrhythmia in BrS patients [34] . Particularly challenging is treatment of electrical storm in BrS patients, which has been anecdotally treated with disopyramide [35] , orciprenaline [36] , and quinine [37] .
Long QT syndrome
To date, more than 700 mutations in 12 genes have been identified in approximately 70% of patients with long QT syndrome (LQTS). However, genetic test results for LQTS can be misleading because rare variants can be nonpathogenic [38] , requiring a common polymorphism in the target gene [39] or a genetic modifier like NOS1AP Genetics of sudden cardiac death syndromes Chopra and Knollmann 197
Key points
Novel gene discoveries have been made in many sudden cardiac death (SCD) syndromes. New genetic SCD animal models have provided novel mechanistic insights in nearly all the major SCD syndromes, which has led to new drug therapies for patients with genetic SCD syndromes. New studies identify genetic contributions to arrhythmia risk after myocardial infarction. Both rare and common variants in cardiac ion channels and other proteins likely contribute to common cardiac phenotypes. [40] to display the phenotype. Furthermore, large genomic rearrangements of the canonical LQTS-susceptibility genes should be suspected in patients with a strong clinical phenotype who fail to reveal point mutations with conventional genetic testing [41] . Compound and digenic heterozygosity causing a more severe phenotype is observed in 5-10% of LQTS patients [42] . Recently, a mutation in the K þ channel Kir3.4 resulting in a channel trafficking defect and reduction in the I KACh current has been described in autosomal dominant LQTS [43 ] . This discovery is noteworthy because, unlike in the atrium, the I KACh current is generally not considered important for repolarization of the ventricle [43 ] . Clinically, echocardiography has been suggested as a complementary tool to QTc assessment in risk stratification of LQTS mutation carriers [44] .
Insight into pathogenesis of putative mutations causing LQTS is usually obtained from studies in heterologous cell expression system or genetic animal models. Due to their inherent limitations, the underlying mechanism by which a mutation causes LQTS may remain undetermined [45 ] or show discrepancy between in-vitro and clinical phenotype [46] . To address this issue, investigators derived pluripotent stem cells from patients with LQTS-1 and directed them to differentiate into cardiac myocytes [45 ] . As a proof of concept, these myocytes did exhibit the abnormal biophysical and pharmacological phenotype that one would expect due to mutated I ks, suggesting that induced pluripotent stem-cell models can recapitulate aspects of genetic cardiac diseases and can be used as an alternative method of studying their phenotype [45 ] . This technique has also been utilized to study LQTS-2 syndrome, in which the patient-specific human-induced pluripotent stem cells not only accurately model the human disease but also help in individualizing drug testing [47] .
Therapeutically, recent work suggests that the late Na þ current blocker ranolazine shortens QT and may be beneficial for LQT patients with Na þ channel mutations (LQT3) [48] .
Short QT syndrome
Short QT syndrome (SQTS) is an inherited primary arrhythmogenic cardiac disorder characterized by abnormally short QT interval and a predisposition to development of atrial and ventricular tachyarrhythmias [49] . Five subtypes have been described due to gain of function mutation in genes encoding K-channels (KCNH2, KCNQ1, and KCNJ2; types 1-3) or loss of function mutation in the gene encoding the L-type Ca channel (CACNA1C) or its beta-subunit CACNB2b (types 4-5) [49] . The common underlying mechanism is a shortening of action potential duration, which can generate a substrate for reentry.
Idiopathic ventricular fibrillation
IVF -spontaneous ventricular fibrillation without identifiable structural or electrical heart disease -may account for up to 10% of sudden death in the young [50] [51] [52] .
Haplotype-sharing analysis has identified a genetic basis for IVF [53 ] . The shared chromosomal segment contained the DPP6 gene, which encodes a putative regulator of the transient outward I to current [54] . DPP6 mRNA levels were increased 20-fold in hearts of human carriers in one study [53 ] . To date, this seems to be a founder risk locus, but nonetheless it suggests that an increase in DPP6 imparts a higher risk for ventricular fibrillation.
Furthermore, previously thought to be a benign and common ECG finding present in up to 5% of the population, three separate case-control studies [55 ,56,57] suggest that 'J-point elevation' (manifested either as terminal QRS slurring or notching, or ST-segment elevation with upper concavity and prominent T waves in inferolateral leads) is significantly more prevalent (16-60%) in patients with IVF. Mutations in genes encoding subunits of the L-type Ca 2þ channel (CACNA1C, CACNB2, and CACNA2D1) [58] and a subunit of the K ATP channel encoded by KCNJ8 [59] have been implicated in this new 'J-wave syndrome' or 'early repolarization syndrome' [60] .
Arrhythmogenic right ventricular cardiomyopathy
ARVC is an autosomal-dominant syndrome with variable penetrance in up to 50% of patients characterized by progressive myocardial atrophy with fibro-fatty replacement predominantly in the right ventricle [61] . Since the first description of mutations in plakoglobin causing ARVC in 2000 [62] , many more desmosomal protein mutations have been discovered [63] . Even though mutations in the desmosomal protein plakophilin-2 (PKP2) are most common (25-40%) in ARVC patients [63, 64] , they may not be pathogenic in isolation, as indicated by reports of low penetrance of some heterozygous PKP2 mutations [65 ] , prevalence of certain disease-causing missense PKP2 mutations in healthy controls [66] , and prevalence of mutations in multiple desmosomal genes in 4-42% of ARVC patients [63,65 ,67] . Additionally, a gene-dose effect is suggested by the requirement of compound or digenic heterozygosity (additional variants in the same or associated desmosomal genes, respectively) in order to manifest an ARVC phenotype [63,65 ,67] , which is also significantly associated with increased likelihood of SCD and left ventricular systolic dysfunction [63, 64, 67] . Furthermore, nonsense or frame-shift mutations in PKP2 alone -in contrast to missense mutations -often do not result in clinical disease, which suggests a dominant-negative effect of missense mutations when compared with haploinsufficiency associated with truncated mutations [63, 65 ] .
Therefore, genotyping in clinical practice should include all the desmosomal proteins even if an index mutation is discovered, especially in patients with a severe phenotype or left ventricular dysfunction [65 ,67] . The latter seems more common with mutations in desmoglein-2 (50%), plakophilin-2 (10%), and desmoplakin [63] .
Dilated cardiomyopathy
Familial DCM is associated with rare variants in more than 20 sarcomeric and structural proteins, but known gene mutations only explain the disease in a small percentage of patients. Not surprisingly, common variants in these genes may also increase susceptibility to DCM [68 ] . Even though considered a separate entity, studies implicate mutations in genes associated with familial DCM in a small subset of patients with peripartum or pregnancy-associated DCM [69, 70 ] .
A recent new addition to the long list of DCM candidate genes is nebulette (NEBL), which encodes a 107 kDa protein that aligns thin filaments and connects them with the myocardial Z-disk. Novel nebulette mutations (K60N, Q128R, G202R, and A592E) were identified in patients with DCM, endocardial fibroelastosis, and cardiac failure [71 ] . Another is dynamin-1-like (Dnm1l) gene, which is known to be critical for mitochondrial fission and has also been implicated in causing DCM by reducing levels of mitochondrial enzyme complexes and cardiac ATP depletion [72] .
Influence of common polymorphisms on DCM susceptibility was evaluated in a case-control study identifying a polymorphism (rs1739843) in intron 2 of the HSPB7 (encoding the small heat shock protein cvHsp, also called HspB7) as being associated with susceptibility to DCM. However, the functional significance of this variant is presently unknown and needs further evaluation [73] . Furthermore, classically implicated in causing ARVC, desmosomal mutations occur in at least 5% of patients with DCM with a phenotype essentially indistinguishable from DCM patients without desmosomal mutations, except for a higher prevalence of exercise-induced ventricular ectopy [74] .
Clinically, it is not uncommon to see the degree of ischemic cardiomyopathy often out of proportion to the amount of overtly infarcted myocardium, suggesting involvement of other mechanisms. One such is prolyl hydroxylase domain-containing protein (PHD) prolyl hydroxylases, which are oxygen-sensitive enzymes that transduce changes in oxygen availability into changes in the stability of the hypoxia-inducible factor (HIF) transcription factor, a master regulator of genes that promote survival in a low-oxygen environment [75] . Inactivation of cardiac-specific PHD and subsequent HIF activation cause structural, histological, and functional changes akin to chronic ischemic cardiomyopathy, suggesting its causal role and possible therapeutic target for pharmacological manipulation in ischemic cardiomyopathy, the leading cause of SCD from an acquired disease [75] .
Hypertrophic cardiomyopathy
Familial HCM is usually caused by mutations in genes encoding sarcomeric proteins. Among them, mutations in b-myosin heavy chain (MHC), cardiac myosin-binding protein C, cardiac troponin I, and cardiac troponin T account for nearly 50% of reported cases.
Recently, missense mutations that cause defective interaction between nexilin and a-actin have been described in HCM [76 ] . Nexilin (NEXN) is a cardiac Z-disc protein that has a crucial function to protect cardiac Z-discs from forces generated within the sarcomere [76 ] . Pathologic hypertrophy in HCM is associated with a-MHC downregulation and b-MHC induction, representing a fetal state of MHC expression. Brg1, a chromatin-remodeling protein, has a critical role in regulating cardiac growth, differentiation, and gene expression and is reactivated by cardiac stresses to induce this pathologic MHC shift [77 ] . Preventing Brg1 re-expression decreases hypertrophy and reverses this pathologic MHC switch, suggesting it to be a potential therapeutic target for cardiac hypertrophy and failure [77 ] . Amidst general cardiac hypertrophy, myocyte enhancer factor-2mediated focal myocyte necrosis and scarring may lead to heterogeneous scarring that predisposes to ventricular tachyarrhythmia [78] . These show that novel structural genes (NEXN) and pathogenic mechanisms in causation of HCM, a common cause of SCD, continue to be discovered, re-emphasizing the importance of future research in this area.
Increased myocardial collagen synthesis in HCM mutation carriers often antedates overt clinical hypertrophy and may identify persons at risk for arrhythmias, sudden death, or heart failure even before manifestation of overt myocardial fibrosis, a hallmark of HCM and a likely substrate for ventricular tachyarrhythmia and heart failure [79 ] . Mechanistically, nonmyocyte activation of transforming growth factor beta (TGF-b) signaling is pivotal for increased fibrosis in HCM [80] . Therefore, prophylactic pharmacologic inhibition of TGF-b cascade may prevent fibrosis and heart failure and warrants further study in patients with sarcomeric gene mutations [80] .
Another independent mechanism for ventricular tachyarrhythmia risk in HCM appears to be the increased myofilament Ca 2þ sensitivity caused by several mutations in troponin T or I. Even in the absence of cardiac remodeling, increased myofilament Ca 2þ sensitization causes reduced effective refractory period, greater beat-to-beat variability of action potential duration (APD), and increased dispersion of ventricular conduction velocities at fast heart rates in mice [81] . This observation has potential therapeutic implications and should be explored further.
Left ventricular noncompaction
Left ventricular noncompaction (LVNC) -a rare disorder characterized by multiple deep trabeculations within the left ventricular myocardium -is increasingly being recognized as a cause of ventricular tachyarrhythmia and SCD in young patients [82] . Overlapping genetic predisposition to LVNC, HCM, and dilated cardiomyopathy, suggesting a continuum of disease associated with sarcomeric gene mutations, has been proposed [83] . Interestingly, distal chromosome deletion at 22q11.2 [84] and 1p36 [85, 86] , though previously associated with atrial and ventricular septal defects, has been more recently described in patients with LVNC.
Conclusion
Genetic testing does not only impact care of inherited SCD syndrome patients but also benefits their often asymptomatic, disease-carrying relatives by institution of prophylactic treatment [87] . At the other end of the spectrum, post-mortem screening for cardiac channelopathies in SCD victims has been advocated; newer technologies are emerging to accomplish this more effectively [88, 89] . Furthermore, discovery of novel SCD syndromes (e.g., IVF) provides the opportunity to decipher the genetic contribution to relatively well characterized clinical ECG phenotypes (e.g., J-wave) [ 
